论文部分内容阅读
目的观察自体CIK细胞联合静脉化疗治疗晚期非小细胞肺癌的效果,以供临床参考。方法以2010年8月～2011年7月在我院接受治疗的晚期非小细胞肺癌患者115例为研究对象,进行随机分组,均接受NP化疗方案。观察组于化疗结束后回输自体CIK细胞。随访1年,观察两组临床疗效、死亡率和生活质量的差异。结果与对照组相比较,观察组有效率、疾病控制率较高,随访期间死亡率较低,QOL评分较高,有显著的统计学差异(P<0.05)。结论采用自体CIK细胞联合化疗治疗晚期非小细胞肺癌,可延长患者生存时间,提高生存质量,具有积极的临床意义。
Objective To observe the effect of autologous CIK cells and intravenous chemotherapy in the treatment of advanced non-small cell lung cancer for clinical reference. Methods One hundred and fifteen patients with advanced non-small cell lung cancer treated in our hospital from August 2010 to July 2011 were enrolled in this study. Patients were randomly assigned to receive NP chemotherapy. The observation group received autologous CIK cells after chemotherapy. One year after follow-up, the differences of clinical efficacy, mortality and quality of life between the two groups were observed. Results Compared with the control group, the observation group had higher effective rate, higher disease control rate, lower follow-up mortality rate, higher QOL score, and significant statistical difference (P <0.05). Conclusion The combination of autologous CIK cells and chemotherapy in the treatment of advanced non-small cell lung cancer can prolong the survival time and improve the quality of life. It has a positive clinical significance.